Halozyme Therapeutics Inc (HALO) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

Total Cash From Operating Activities Chart for Halozyme Therapeutics Inc

Halozyme Therapeutics Inc (HALO) operating cash flow for FY2025 was USD 651.6M, a 36.0% change from FY2024. Halozyme Therapeutics Inc's operating cash flow moved from USD -34.4K in 2001 to USD 651.6M in 2025 over 24 years. Operating cash flow compound annual growth rate: 5-year CAGR of 63.7%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$12.45B
Implied Share Price
$109.72
Enterprise Value
$14.68B
Revenue (TTM)
$1.66B
EBITDA
$1.05B
Profit Margin
24.86%
Trailing P/E
31.71
Forward P/E
11.45
Price/Book (MRQ)
88.91
Price/Sales (TTM)
7.49
EV/EBITDA
11.80
EV/Revenue
8.82
Dividend Yield
—
Book Value
$1.26
Free Cash Flow (FY2025)
$644.59M
Free Cash Flow Yield
5.18%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.